Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2015 August;67(4) > Minerva Ginecologica 2015 August;67(4):335-52

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

REVIEWS   

Minerva Ginecologica 2015 August;67(4):335-52

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Chemoprevention of breast cancer among women at elevated risk as defined by Gail Score

Micallef S. 1, Micallef D. 1, Schembri-Wismayer P. 1, Brincat M. P. 2, Calleja-Agius J. 1

1 Department of Anatomy, Faculty of Medicine and Surgery, University of Malta, Tal‑Qroqq, Msida, Malta; 2 Department of Obstetrics and Gynecology, Mater Dei Hospital, Birkirkara, Malta


PDF


The risk of an individual woman to develop breast cancer over a 5-year period can be estimated using the Gail Model. The risk factors included in this model effectively classify patients into two different subgroups. One subgroup comprises patients at increased risk because of increased exposure to estrogen. These women are more likely to benefit from endocrine chemopreventive therapies, namely selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). The second subgroup comprises women who have inherited genetic mutations that predispose them to breast cancer. Chemoprevention in these patients is more likely to be achieved by novel agents, such as lapatinib, gefitinib, fenretinide, rexinoids and poly(ADP-ribose) polymerase (PARP) -inhibitors.

top of page